Psoriasis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Psoriasis (US)
The treatment of adult psoriasis represents an increasingly lucrative market for nonconventional systemic therapies in the moderate to severe space, for which conventional systemic and topical treatments are insufficient. The launch of newer, more-effective biologics (e.g., Eli Lilly’s IL-17 inhibitor Taltz, AbbVie’s latest-in-class IL-23 inhibitor Skyrizi, UCB’s IL-17 A/F dual inhibitor Bimzelx) has eroded the market share of long-established biologics such as AbbVie’s TNF-alpha inhibitor Humira, Johnson & Johnson Innovative Medicine’s IL-12/23 inhibitor Stelara, and Novartis’s IL-17 inhibitor Cosentyx. The emergence of multiple biosimilars of adalimumab is also increasing the competition in this market. Amgen’s PDE-4 inhibitor Otezla, the only oral targeted therapy for many years, is firmly enduring the competition from Sotyktu, an oral TYK2 inhibitor that showed clinical superiority to Otezla in two head-to-head trials.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed adult psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed adult psoriasis patients?
- How have newer targeted agents such as Bimzelx and Sotyktu been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of adult psoriasis patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?
- What percentage of adult psoriasis patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Markets covered: United States
Key companies: AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, UCB
Key drugs: Humira, Taltz, Bimzelx, Tremfya, Skyrizi, Otezla, Sotyktu, Vtama, Zoryve
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:
- Understand patient flow between lines of therapy.
- Evaluate your brand share against competitors.
- Accurately assess your source of business.
- Quantify opportunities at different stages of the treatment algorithm.
